Nice update – IMHO it shows that the team is working hard in...

Nice update – IMHO it shows that the team is working hard in the background and making the right choices.

1) New IV formulation

Progressing well - but - new formulation will inform the solid tumour (Breast Cancer) trial, where a CVC is not used, so it may start much later than originally expected (pushed from Q2 2023 to Q2 2024?) Also, it looks like the next stage of the Chaim Cheba trial will pause until the new formulation is available. This might create delays in the final results (I think final results were expected Q3 2024?). We can still expect final readings of the first stage which is good.

This is not a bad thing overall. But, from a shareholder perspective, it looks like clinical progress is still a few years away (and we know this is what the market wants to see for a proper re-rate).

2) Profiling theactivity of bisantrene in multiple cancer cases:

“Bisantrene has shown entirelyboard and potent cell-killing activity across a variety of cancer types/indications” – this is very exciting. Can’t wait for more details. Also, it will be interesting to see bisantrene cell-killing activity matched with the indication’s prognosis as well as individual FTO expression in biopsies.

3) Chaim Sheba Israel

Two more patients to meet first stage of the Simon two stage decision point! Observations have been compelling.Good! Short term catalyst?

4) EMD AML recruitmentissues:

Noted about the amendment to broaden the scope. But – if recruitment is an issue, why not open more sites in larger cities?

5) The great absentee

So far, total silence on the human FTO biomarkers & company diagnostic?